Advanced glycation end products and neurodegenerative diseases: Mechanisms and perspective

Published:March 14, 2012DOI:


      The age-related neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's diseases are characterized by the abnormal accumulation or aggregation of proteins. Advanced glycation end products (AGEs) are proteins or lipids that become glycated after exposure to sugars. The formation of AGEs promotes the deposition of proteins due to the protease resistant crosslinking between the peptides and proteins. Several proteins implicated in neurodegenerative diseases such as amyloid β, tau, α-synuclein, and prions are glycated and the extent of glycation is correlated with the pathologies of the patients. These data suggest that AGEs contribute to the development of neurodegenerative diseases. In this review we summarize recent advances on the investigation of the roles of AGEs in neurodegenerative diseases, with special focus on Alzheimer's and Parkinson's diseases. It is clear that AGEs modification triggers the abnormal deposition and accumulation of the modified proteins, which in turn sustain the local oxidative stress and inflammatory response, eventually leading to the pathological and clinical aspects of neurodegenerative diseases. Further characterization of the molecular mechanisms responsible for AGEs mediated neurotoxicity will provide important clues on the development of novel strategies for the prevention and treatment of neurodegenerative diseases.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Yamamoto A.
        • Simonsen A.
        The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration.
        Neurobiol Dis. 2011; 43: 17-28
        • Calabrese V.
        • Cornelius C.
        • Mancuso C.
        • Lentile R.
        • Stella A.M.
        • Butterfield D.A.
        Redox homeostasis and cellular stress response in aging and neurodegeneration.
        Methods Mol Biol. 2010; 610: 285-308
        • Samson F.E.
        • Nelson S.R.
        The aging brain, metals and oxygen free radicals.
        Cell Mol Biol (Noisy-le-Grand). 2000; 46: 699-707
        • Schulz J.B.
        • Lindenau J.
        • Seyfried J.
        • Dichgans J.
        Glutathione, oxidative stress and neurodegeneration.
        Eur J Biochem. 2000; 267: 4904-4911
        • Vicente M.H.
        • Outeiro T.F.
        The sour side of neurodegenerative disorders: the effects of protein glycation.
        J Pathol. 2010; 221: 13-25
        • Srikanth V.
        • Maczurek A.
        • Phan T.
        • Steele M.
        • Westcott B.
        • Juskiw D.
        • et al.
        Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
        Neurobiol Aging. 2011; 32: 763-777
        • Grillo M.A.
        • Colombatto S.
        Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases.
        Amino Acids. 2008; 35: 29-36
        • Richard J.P.
        Mechanism for the formation of methylglyoxal from triosephosphates.
        Biochem Soc Trans. 1993; 21: 549-553
        • Thornalley P.J.
        Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification — a role in pathogenesis and antiproliferative chemotherapy.
        Gen Pharmacol. 1996; 27: 565-573
        • Chang T.
        • Wu L.
        Methylglyoxal, oxidative stress, and hypertension.
        Can J Physiol Pharmacol. 2006; 84: 1229-1238
        • Thornalley P.J.
        Methylglyoxal, glyoxalases and the development of diabetic complications.
        Amino Acids. 1994; 6: 15-23
        • Thornalley P.
        • Wolff S.
        • Crabbe J.
        • Stern A.
        The autoxidation of glyceraldehyde and other simple monosaccharides under physiological conditions catalysed by buffer ions.
        Biochim Biophys Acta. 1984; 797: 276-287
        • Thornalley P.J.
        Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors.
        Chem Biol Interact. 1998; 111–112: 137-151
        • Niwa T.
        3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication.
        J Chromatogr B Biomed Sci Appl. 1999; 731: 23-36
        • Alexiou P.
        • Chatzopoulou M.
        • Pegklidou K.
        • Demopoulos V.J.
        RAGE: a multi-ligand receptor unveiling novel insights in health and disease.
        Curr Med Chem. 2010; 17: 2232-2252
        • Neeper M.
        • Schmidt A.M.
        • Brett J.
        • Yan S.D.
        • Wang F.
        • Pan Y.C.
        • et al.
        Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins.
        J Biol Chem. 1992; 267: 14998-15004
        • Srikrishna G.
        • Huttunen H.J.
        • Johansson L.
        • Weigle B.
        • Yamaguchi Y.
        • Rauvala H.
        • et al.
        N-Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth.
        J Neurochem. 2002; 80: 998-1008
        • Zhang L.
        • Postina R.
        • Wang Y.
        Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease.
        Cell Mol Life Sci. 2009; 66: 3923-3935
        • Bierhaus A.
        • Humpert P.M.
        • Morcos M.
        • Wendt T.
        • Chavakis T.
        • Arnold B.
        • et al.
        Understanding RAGE, the receptor for advanced glycation end products.
        J Mol Med (Berl). 2005; 83: 876-886
        • Li J.
        • Schmidt A.M.
        Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products.
        J Biol Chem. 1997; 272: 16498-16506
        • Cho H.J.
        • Son S.M.
        • Jin S.M.
        • Hong H.S.
        • Shin D.H.
        • Kim S.J.
        • et al.
        RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model.
        FASEB J. 2009; 23: 2639-2649
        • Kim S.W.
        • Lim C.M.
        • Kim J.B.
        • Shin J.H.
        • Lee S.
        • Lee M.
        • et al.
        Extracellular HMGB1 released by NMDA treatment confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway.
        Neurotox Res. 2011; 20: 159-169
        • Huttunen H.J.
        • Kuja-Panula J.
        • Rauvala H.
        Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation.
        J Biol Chem. 2002; 277: 38635-38646
        • Xu Y.
        • Toure F.
        • Qu W.
        • Lin L.
        • Song F.
        • Shen X.
        • et al.
        Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages.
        J Biol Chem. 2010; 285: 23233-23240
        • Hudson B.I.
        • Kalea A.Z.
        • Del M.A.M.
        • Harja E.
        • Boulanger E.
        • D'Agati V.
        • et al.
        Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42.
        J Biol Chem. 2008; 283: 34457-34468
        • Tanzi R.E.
        A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders.
        J Clin Invest. 1999; 104: 1175-1179
        • Gandy S.
        The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease.
        J Clin Invest. 2005; 115: 1121-1129
        • Li J.J.
        • Voisin D.
        • Quiquerez A.L.
        • Bouras C.
        Differential expression of advanced glycosylation end-products in neurons of different species.
        Brain Res. 1994; 641: 285-288
        • Munch G.
        • Mayer S.
        • Michaelis J.
        • Hipkiss A.R.
        • Riederer P.
        • Muller R.
        • et al.
        Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide.
        Biochim Biophys Acta. 1997; 1360: 17-29
        • Ko S.Y.
        • Lin Y.P.
        • Lin Y.S.
        • Chang S.S.
        Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species.
        Free Radic Biol Med. 2010; 49: 474-480
        • Schipper H.M.
        Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment.
        Neurobiol Aging. 2011; 32: 778-790
        • Li Y.M.
        • Dickson D.W.
        Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease.
        Neurosci Lett. 1997; 226: 155-158
        • Ledesma M.D.
        • Bonay P.
        • Avila J.
        Tau protein from Alzheimer's disease patients is glycated at its tubulin-binding domain.
        J Neurochem. 1995; 65: 1658-1664
        • Li X.H.
        • Lv B.L.
        • Xie J.Z.
        • Liu J.
        • Zhou X.W.
        • Wang J.Z.
        AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation.
        Neurobiol Aging. 2011; ([Electronic publication ahead of print])
        • Lees A.J.
        • Hardy J.
        • Revesz T.
        Parkinson's disease.
        Lancet. 2009; 373: 2055-2066
        • Forno L.S.
        Neuropathology of Parkinson's disease.
        J Neuropathol Exp Neurol. 1996; 55: 259-272
        • Braak H.
        • Del T.K.
        • Rub U.
        • de Vos R.A.
        • Jansen S.E.N.
        • Braak E.
        Staging of brain pathology related to sporadic Parkinson's disease.
        Neurobiol Aging. 2003; 24: 197-211
        • Outeiro T.F.
        • Kontopoulos E.
        • Altmann S.M.
        • Kufareva I.
        • Strathearn K.E.
        • Amore A.M.
        • et al.
        Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.
        Science. 2007; 317: 516-519
        • Lee D.
        • Park C.W.
        • Paik S.R.
        • Choi K.Y.
        The modification of alpha-synuclein by dicarbonyl compounds inhibits its fibril-forming process.
        Biochim Biophys Acta. 2009; 1794: 421-430
        • Padmaraju V.
        • Bhaskar J.J.
        • Prasada R.U.J.
        • Salimath P.V.
        • Rao K.S.
        Role of advanced glycation on aggregation and DNA binding properties of alpha-synuclein.
        J Alzheimers Dis. 2011; 24: 211-221
        • Chen L.
        • Wei Y.
        • Wang X.
        • He R.
        Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products.
        PLoS One. 2010; 5: e9052
        • Dalfo E.
        • Portero-Otin M.
        • Ayala V.
        • Martinez A.
        • Pamplona R.
        • Ferrer I.
        Evidence of oxidative stress in the neocortex in incidental Lewy body disease.
        J Neuropathol Exp Neurol. 2005; 64: 816-830
        • Castellani R.
        • Smith M.A.
        • Richey P.L.
        • Perry G.
        Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease.
        Brain Res. 1996; 737: 195-200
        • Kaufmann E.
        • Boehm B.O.
        • Sussmuth S.D.
        • Kientsch-Engel R.
        • Sperfeld A.
        • Ludolph A.C.
        • et al.
        The advanced glycation end-product N epsilon-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
        Neurosci Lett. 2004; 371: 226-229
        • Gomes R.
        • Sousa S.M.
        • Quintas A.
        • Cordeiro C.
        • Freire A.
        • Pereira P.
        • et al.
        Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy.
        Biochem J. 2005; 385: 339-345
        • Sasaki N.
        • Takeuchi M.
        • Chowei H.
        • Kikuchi S.
        • Hayashi Y.
        • Nakano N.
        • et al.
        Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt–Jakob disease with prion plaques.
        Neurosci Lett. 2002; 326: 117-120
        • Anzilotti S.
        • Giampa C.
        • Laurenti D.
        • Perrone L.
        • Bernardi G.
        • Melone M.A.
        • et al.
        Immunohistochemical localization of receptor for advanced glycation end (RAGE) products in the R6/2 mouse model of Huntington's disease.
        Brain Res Bull. 2011; 87: 350-358
        • Li G.
        • Chang M.
        • Jiang H.
        • Xie H.
        • Dong Z.
        • Hu L.
        Proteomics analysis of methylglyoxal-induced neurotoxic effects in SH-SY5Y cells.
        Cell Biochem Funct. 2011; 29: 30-35
        • Nin J.W.
        • Jorsal A.
        • Ferreira I.
        • Schalkwijk C.G.
        • Prins M.H.
        • Parving H.H.
        • et al.
        Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
        Diabetes Care. 2011; 34: 442-447
        • Rahmadi A.
        • Steiner N.
        • Munch G.
        Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease.
        Clin Chem Lab Med. 2011; 49: 385-391